NASDAQ:GNMK GenMark Diagnostics (GNMK) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free GNMK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$24.04▼$24.0450-Day Range$23.89▼$24.0452-Week Range$8.42▼$24.25VolumeN/AAverage Volume2.70 million shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GenMark Diagnostics alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About GenMark Diagnostics Stock (NASDAQ:GNMK)GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.Read More Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! GNMK Stock News HeadlinesMarch 15, 2024 | finance.yahoo.comQuest Diagnostics Incorporated (DGX)July 8, 2023 | nbcnews.comYouTube star Grace Helbig shares breast cancer diagnosisApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.June 6, 2023 | usatoday.comStudy finds brain 'signature' for chronic pain, which could improve diagnosis, treatmentJune 2, 2023 | lse.co.ukGenmark Diagnos Share ChatMay 28, 2023 | usatoday.comWhen autism isn't diagnosed until adulthood: 'It takes a mental crisis to get diagnosed'April 29, 2023 | nypost.comDoctor who helped broaden autism spectrum ‘very sorry’ for over-diagnosisApril 27, 2023 | benzinga.comWith 11.1% CAGR, Molecular Diagnostics Market to Surpass US$ 37.19 Bn by 2028 - Global Analysis by TMRApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.February 23, 2023 | nypost.comBruce Willis’ family reveals ‘cruel’ dementia diagnosisFebruary 18, 2023 | cbsnews.comWhat is frontotemporal dementia? Bruce Willis' diagnosis, explainedFebruary 18, 2023 | cbsnews.comCelebrities react to Bruce Willis' frontotemporal dementia diagnosisJanuary 26, 2023 | finance.yahoo.comHepatitis B and C diagnostics market size to increase by USD 2,055.79 million; North America to account for 47% of market growth - TechnavioJanuary 17, 2023 | nypost.comChristina Applegate says she’s nervous about first awards show since MS diagnosisJanuary 10, 2023 | finance.yahoo.comGravity Diagnostics Appoints Karen Hargett as Chief People OfficerDecember 31, 2022 | finance.yahoo.comInfectious Disease Diagnostics Global Market Report 2022: Increasing Availability and Affordability of Rapid Diagnostic Kits Presents OpportunitiesOctober 30, 2022 | finance.yahoo.comMolecular Diagnostics Market is Booming and Expected to Reach USD 37.19 Billion to 2028, notes TMR StudyOctober 16, 2022 | newsweek.comGena Tew Reveals Whether She's Able To Have Children After AIDS DiagnosisOctober 5, 2022 | finance.yahoo.comBoston Heart Diagnostics Launches LipoMap™: One of the Most Comprehensive Assessments of Lipid Metabolism AvailableJuly 30, 2022 | thestreet.comGenMark Diagnostics, Inc. NewsMay 6, 2022 | benzinga.comSpecific Diagnostics announces that Nathan Clark, former GenMark Sales Leader, joins Specific Diagnostics as Strategic Account Director, US EastSee More Headlines Receive GNMK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GenMark Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/25/2021Today4/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:GNMK CUSIPN/A CIK1487371 Webwww.genmarkdx.com Phone760-448-4300FaxN/AEmployees618Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,350,000.00 Net Margins-16.95% Pretax MarginN/A Return on Equity-39.36% Return on Assets-13.02% Debt Debt-to-Equity Ratio0.75 Current Ratio4.33 Quick Ratio3.84 Sales & Book Value Annual Sales$88.02 million Price / Sales19.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book114.48Miscellaneous Outstanding Shares73,086,000Free FloatN/AMarket Cap$1.76 billion OptionableOptionable Beta3.02 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Scott Mendel (Age 54)Pres & CEO Comp: $506.61kMr. John Frederick Ek (Age 45)Chief Financial Officer Comp: $423.71kMr. Michael Gleeson (Age 46)Sr. VP of Corp. Accounts Comp: $395.17kMr. Abe ChohanSr. VP of OperationsMr. Eric Stier (Age 45)Sr. VP, Gen. Counsel & Sec. Mr. Scott O'Brien (Age 45)Sr. VP of Global Marketing & International Sales Ms. Hollis Winkler (Age 46)VP of HR Mr. Tyler Jensen (Age 52)Sr. VP of Engineering & Product Technical Support More ExecutivesKey CompetitorsLuminexNASDAQ:LMNXAlphatecNASDAQ:ATECLeMaitre VascularNASDAQ:LMATTandem Diabetes CareNASDAQ:TNDMNovoCureNASDAQ:NVCRView All Competitors GNMK Stock Analysis - Frequently Asked Questions How were GenMark Diagnostics' earnings last quarter? GenMark Diagnostics, Inc. (NASDAQ:GNMK) announced its earnings results on Thursday, February, 25th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.04. The medical equipment provider earned $50.08 million during the quarter, compared to analyst estimates of $50 million. GenMark Diagnostics had a negative net margin of 16.95% and a negative trailing twelve-month return on equity of 39.36%. What is Scott Mendel's approval rating as GenMark Diagnostics' CEO? 4 employees have rated GenMark Diagnostics Chief Executive Officer Scott Mendel on Glassdoor.com. Scott Mendel has an approval rating of 75% among the company's employees. What other stocks do shareholders of GenMark Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Miragen Therapeutics (MGEN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO), CBL & Associates Properties (CBL) and Hallador Energy (HNRG). This page (NASDAQ:GNMK) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GenMark Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.